PREMUROSA · Precision medicine for muscoloskeletal regeneration, prosthetics and active ageing

Precision medicine for muscoloskeletal regeneration, prosthetics and active ageing

Musculoskeletal diseases are reported to affect roughly half of the world’s population over 60, strongly impacting the quality of life. They are a significant burden on individuals, healthcare and welfare systems, with huge direct and indirect costs. The treatment of musculoskeletal disorders is often based either on prosthetic rehabilitation or regenerative surgical procedures, including scaffold implantation. In both cases, individual tissue healing and regeneration response, and the appropriateness of the implanted device, markedly affect the outcome. Personalised medicine has evolved as a model aiming to transform translational research into a patient-specific (“precise”) concept, which incorporates tailored diagnostic measures and customised targeted therapies, improving the clinical success rate. This approach is currently applied in some medical fields such as Oncology. However, it has received poor attention in orthopaedics where the concept of “personalisation” is still mostly limited to a mere adaptation of the device geometry to the patient anatomy without considering any patient-specific capability in tissue regeneration. In addition, despite the significant improvement in developing multi-functional smart biomaterials and medical devices for tissue regeneration by classical “design and engineering” approaches, the pre-clinical models for the biological assessment of their efficacy have not followed the same evolution. Because of that, no more than one-third of innovations are translated to clinical practice. The complexity of the regenerative process and the difficulty in predicting and controlling the interaction between tissue and biomaterial and the lack of reliable and rapid execution preclinical models addressed to predict the clinical performances are certainly responsible for these gaps. The aim of PREMUROSA (Precision medicine for musculoskeletal regeneration, prosthetics, and active ageing) is thus to help precise patient-centred application of regenerative treatments by developing new in-vitro tests and decision support systems (DSS), while training 13 young scientists (ESRs) with multidisciplinary approach and interaction.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз